Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK — Four New York shops have advanced in TAP Pharmaceutical Products’$100 million Prevacid review: McCann-Erickson, Ogilvy & Mather, Deutsch and Merkley Newman Harty & Partners, sources said.
Two other New York shops that responded to TAP’s RFP–TBWA\Chiat\Day and Young & Rubicam–were eliminated last week, said sources.
Last Thursday and Friday, client executives briefed the four finalists in preparation for final pitches, which are scheduled for mid-September, according to sources. The briefings took place at the agencies, each one lasting up to three hours.
The
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in